Patients With ACS
ST2 is a strong predictor of cardiovascular death and risk of developing new heart failure in ST Elevation Myocardial Infarction (STEMI) & NSTE-ACS patients. In patients presenting with Acute Coronary Syndrome (ACS), those in the highest quartile (above 35 ng/ml) have more than 3 times higher risk of cardiovascular death and new heart failure at 30 days, than those in the lower quartiles. At one year, there is a relative risk of 2.3 for adverse outcomes.
ST2 is an active participant in the cardiac remodeling pathway and could identify which patients will respond to Eplerenone, or other therapies that reverse myocardial fibrosis.
Read more about this topic: ST2 Cardiac Biomarker
Famous quotes containing the word patients:
“The doctor should be opaque to his patients and, like a mirror, should show them nothing but what is shown to him.”
—Sigmund Freud (1856–1939)